Functional expression and comparative characterization of four feline P450 cytochromes using fluorescent substrates

References

• Bailey J, Thew M, Balls M. (2015). Predicting human drug toxicity and safety via animal tests: can any one species predict drug toxicity in any other, and do monkeys help? Altern Lab Anim 43:393–403
   PubMed Web of Science ®Google Scholar
• Baratta MT, Zaya MJ, White JA, Locuson CW. (2010). Canine CYP2B11 metabolizes and is inhibited by anesthetic agents often co-administered in dogs. J Vet Pharmacol Ther 33:50–5
   PubMed Web of Science ®Google Scholar
• Baririan N, Desager JP, Petit M, Horsmans Y. (2006). CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination. J Pharm Biomed Anal 40:211–14
   PubMed Web of Science ®Google Scholar
• Barnes HJ. (1996). Maximizing expression of eukaryotic cytochrome P450s in Escherichia coli. Methods Enzymol 272:3–14
   PubMed Web of Science ®Google Scholar
• Bièche I, Narjoz C, Asselah T, et al. (2007). Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 17:731–42
   PubMed Web of Science ®Google Scholar
• Chauret N, Gauthier A, Martin J, Nicoll-Griffith DA. (1997). In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 25:1130–36
   PubMed Web of Science ®Google Scholar
• Court MH. (2013). Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms. Vet Clin North Am Small Anim Pract 43:1039–54
   PubMed Web of Science ®Google Scholar
• Court MH, Greenblatt DJ. (2000). Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. Pharmacogenetics 10:355–69
   PubMedGoogle Scholar
• Crespi CL, Miller VP, Penman BW. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188–90
   PubMed Web of Science ®Google Scholar
• Donato MT, Jiménez N, Castell JV, Gómez-Lechón MJ. (2004). Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos 32:699–706
   PubMed Web of Science ®Google Scholar
• Galetin A, Houston JB. (2006). Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220–29
   PubMed Web of Science ®Google Scholar
• Heikkinen AT, Friedlein A, Lamerz J, et al. (2012). Mass spectrometry-based quantification of CYP enzymes to establish in vitro/in vivo scaling factors for intestinal and hepatic metabolism in beagle dog. Pharm Res 29:832–42
   Web of Science ®Google Scholar
• Honda K, Komatsu T, Koyama F, et al. (2011). Expression of two novel cytochrome P450 3A131 and 3A132 in liver and small intestine of domestic cats. J Vet Med Sci 73:1489–92
   PubMed Web of Science ®Google Scholar
• Hosaka S, Murayama N, Satsukawa M, et al. (2015). Evaluation of 89 compounds for identification of substrates for cynomolgus monkey CYP2C76, a new bupropion/nifedipine oxidase. Drug Metab Dispos 43:27–33
   PubMed Web of Science ®Google Scholar
• Huang YC, Colaizzi JL, Bierman RH, et al. (1986). Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 30:206–10
   PubMed Web of Science ®Google Scholar
• Iwata H, Fujita K, Kushida H, et al. (1998). High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol 55:1315–25
   PubMed Web of Science ®Google Scholar
• Kajbaf M, Longhi R, Montanari D, et al. (2011). A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry. Drug Metab Lett 5:30–9
   PubMedGoogle Scholar
• Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. (1999). CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716–27
   PubMed Web of Science ®Google Scholar
• Komatsu T, Honda K, Kubota A, et al. (2010). Molecular cloning and expression of cytochrome P450 2D6 in the livers of domestic cats. J Vet Med Sci 72:1633–6
   PubMed Web of Science ®Google Scholar
• Lewis DF, Eddershaw PJ, Dickins M, et al. (1998). Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chem Biol Interact 115:175–99
   PubMed Web of Science ®Google Scholar
• Lewis DFV, Ito Y. (2008). Cytochrome P450 Structure and Function: an evolutionary perspective. In: Ioannides C, eds. Cytochromes P450: role in the metabolism and toxicity of drugs and other xenobiotics. Cambridge: RSC publishing, 3–45
   Google Scholar
• Locuson CW, Ethell BT, Voice M, et al. (2009). Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase. Drug Metab Dispos 37:457–61
   PubMed Web of Science ®Google Scholar
• Lu C, Li AP. (2001). Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 134:271–81
   PubMed Web of Science ®Google Scholar
• MacDonald ML, Rogers QR, Morris JG. (1984). Nutrition of the domestic cat, a mammalian carnivore. Annu Rev Nutr 4:521–62
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S, Velama U, Parmar J, et al. (2014). A current review of cytochrome P450 interactions of psychotropic drugs. Ann Clin Psychiatry 26:120–38
   PubMed Web of Science ®Google Scholar
• Martínez C, Albet C, Agúndez JA, et al. (1999). Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 65:369–76
   PubMed Web of Science ®Google Scholar
• Martinez MN, Antonovic L, Court M, et al. (2013). Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metab Rev 45:218–30
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Kawaguchi Y. (2013). Time-dependent inhibition of CYP3A4 by sertraline, a selective serotonin reuptake inhibitor. Biopharm Drug Dispos 34:423–30
   PubMed Web of Science ®Google Scholar
• Mawby DI, Whittemore JC, Fowler LE, Papich MG. (2016). Posaconazole pharmacokinetics in healthy cats after oral and intravenous administration. J Vet Intern Med 30:1703–7
   PubMed Web of Science ®Google Scholar
• McLaughlin LA, Dickmann LJ, Wolf CR, Henderson CJ. (2008). Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos 36:1322–31
   PubMed Web of Science ®Google Scholar
• Mealey KL, Jabbes M, Spenser E, Akey JM. (2008). Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine. Xenobiotica 38:1305–12
   PubMed Web of Science ®Google Scholar
• Milanova A, Lashev L. (2002). Pharmacokinetics of oleandomycin in dogs after intravenous or oral administration alone and after pretreatment with metamizole or dexamethasone. Vet Res Commun 26:61–71
   PubMed Web of Science ®Google Scholar
• Mohri T, Nakajima M, Fukami T, et al. (2010). Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 79:1045–52
   PubMed Web of Science ®Google Scholar
• Nebbia C, Dacasto M, Rossetto Giaccherino A, et al. (2003). Comparative expression of liver cytochrome P450-dependent monooxygenases in the horse and in other agricultural and laboratory species. Vet J 165:53–64
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Yerino P, Kazmi F, et al. (2011). The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 39:2020–33
   PubMed Web of Science ®Google Scholar
• Okamatsu G, Komatsu T, Kubota A, et al. (2015). Identification and functional characterization of novel feline cytochrome P450 2A. Xenobiotica 45:503–10
   PubMed Web of Science ®Google Scholar
• Okamatsu G, Komatsu T, Ono Y, et al. (2016). Characterization of feline cytochrome P450 2B6. Xenobiotica 1–10. [Epub ahead of print]. doi: 10.3109/00498254.2016.1145754
   PubMed Web of Science ®Google Scholar
• Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–6
   PubMed Web of Science ®Google Scholar
• Papich MG. (2010). Saunders handbook of veterinary drugs: small and large animal. 3rd ed. Philadelphia: Saunders
   Google Scholar
• Pearce R, Greenway D, Parkinson A. (1992). Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch Biochem Biophys 298:211–25
   PubMed Web of Science ®Google Scholar
• Plumb DC. (2011). Plumb's veterinary drug handbook. 7th ed. Hoboken: Wiley-Blackwell
   Google Scholar
• Pritchard MP, McLaughlin L, Friedberg T. (2006). Establishment of functional human cytochrome P450 monooxygenase systems in Escherichia coli. In: Phillips IR, Elizabeth AS, eds. Methods in molecular biology. New Jersey: Human Press, 19–29
   Google Scholar
• Sasaki K, Shimoda M. (2015). Possible drug-drug interaction in dogs and cats resulted from alteration in drug metabolism: a mini review. J Adv Res 6:383–2
   PubMed Web of Science ®Google Scholar
• Shah SS, Sanda S, Regmi NL, et al. (2007). Characterization of cytochrome P450-mediated drug metabolism in cats. J Vet Pharmacol Ther 30:422–28
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23
   PubMed Web of Science ®Google Scholar
• Stephens ES, Walsh AA, Scott EE. (2012). Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes. Drug Metab Dispos 40:1797–802
   PubMed Web of Science ®Google Scholar
• Stresser DM, Turner SD, Blanchard AP, et al. (2002). Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos 30:845–52
   PubMed Web of Science ®Google Scholar
• Tanaka N, Miyasho T, Shinkyo R, et al. (2006). cDNA cloning and characterization of feline CYP1A1 and CYP1A2. Life Sci 79:2463–73
   PubMed Web of Science ®Google Scholar
• Tanaka N, Shinkyo R, Sakaki T, et al. (2005). Cytochrome P450 2E polymorphism in feline liver. Biochim Biophys Acta 1726:194–205
   PubMed Web of Science ®Google Scholar
• Ueng YF, Shimada T, Yamazaki H, Guengerich FP. (1995). Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem Res Toxicol 8:218–25
   PubMed Web of Science ®Google Scholar
• Uno T, Nakao A, Masuda S, et al. (2006). Modification of small molecules by using cytochrome P450 expressed in Escherichia coli. J Ind Microbiol Biotechnol 33:1043–50
   PubMed Web of Science ®Google Scholar
• van Beusekom CD, Schipper L, Fink-Gremmels J. (2010). Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs. J Vet Pharmacol Ther 33:519–27
   PubMed Web of Science ®Google Scholar
• Walsky RL, Astuccio AV, Obach RS. (2006). Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 46:1426–38
   PubMed Web of Science ®Google Scholar
• Yun CH, Yim SK, Kim DH, Ahn T. (2006). Functional expression of human cytochrome P450 enzymes in Escherichia coli. Curr Drug Metab 7:411–29
   PubMed Web of Science ®Google Scholar
• Yuan R, Madani S, Wei XX, et al. (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–19
   PubMed Web of Science ®Google Scholar
• Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. (2001). Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29:897–902
   PubMed Web of Science ®Google Scholar
• Zhang K, Kohno S, Kuroha M, et al. (2006). Clinical oral doses of dexamethasone decreases intrinsic clearance of quinidine, a cytochrome P450 3A substrate in dogs. J Vet Med Sci 68:903–7
   PubMed Web of Science ®Google Scholar
• Zhang W, Ramamoorthy Y, Kilicarslan T, et al. (2002). Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 30:314–18
   PubMed Web of Science ®Google Scholar
• Zhou SF, Yang LP, Zhou ZW, et al. (2009). Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. Aaps J 11:481–94
   PubMed Web of Science ®Google Scholar
• Zhou D, Linnenbach AJ, Liu R, et al. (2010). Expression and characterization of dog cytochrome P450 2A13 and 2A25 in baculovirus-infected insect cells. Drug Metab Dispos 38:1015–18
   PubMed Web of Science ®Google Scholar